Search
Formoterol
go.drugbank.com/drugs/DB00983ApprovedInvestigational[A189528] A major clinical advantage of formoterol over other inhaled beta-agonists is its rapid onset of action (2-3 minutes), which is at least as fast as [salbutamol], combined with a long duration … [L10986] It acts on bronchial smooth muscle to dilate and relax airways, and is administered as a racemic mixture of its active (R;R)- and inactive (S;S)-enantiomers.
Mixtures: FIXCORT 9/320 MG CAPSAIR INHALASYON İÇİN TOZ İÇEREN KAPSÜL, 60 ADET, FIXCORT 9/320 MG CAPSAIR INHALASYON İÇİN TOZ İÇEREN KAPSÜL, 120 ADETCategories: Adrenergic beta-2 Receptor Agonists, Selective Beta 2-adrenergic Agonists4-(2-AMINOPHENYL)-4-OXOBUTANOIC ACID
go.drugbank.com/drugs/DB08060ExperimentalSynonyms: 4-(2-AMINOPHENYL)-4-OXOBUTANOIC ACIDUmeclidinium
go.drugbank.com/drugs/DB09076ApprovedInvestigational[A7715] Maintenance of the airway is controlled by the parasympathetic nervous system, particularly by the abundance of the muscarinic subtype 3 (M3) in the airway smooth muscle. … COPD is a progressive obstructive lung disease characterized by shortness of breath, cough, sputum production, and chronically poor airflow with a forced expiratory volume in 1 second (FEV1) of less than
Mixtures: ANORO ELLIPTA 62.5 MCG + 25 MCG KULLANIMA HAZIR INHALASYON TOZU, 3 X 30 DOZ, ANORO ELLIPTA 62.5 MCG + 25 MCG KULLANIMA HAZIR INHALASYON TOZU, 30 DOZCategories: Cytochrome P-450 Substrates, P-glycoprotein substratesAdagrasib
go.drugbank.com/drugs/DB15568ApprovedInvestigational[A254052] In a phase I/IB clinical study that included patients with KRAS<sup>G12C</sup>-mutated advanced solid tumors (NCT03785249), adagrasib exhibited anti-tumor activity. … [A254052,A254057,A254946] In February 2022, the FDA accepted a new drug application (NDA) for adagrasib for the treatment of patients with previously treated KRAS<sup>G12C</sup>–positive NSCLC.
Categories: P-glycoprotein inhibitors, Cytochrome P-450 SubstratesSynonyms: ((2s)-4-(7-(8-chloronaphthalen-1-yl)-2-(((2s)-1- methylpyrrolidin-2-yl)methoxy)-5,6,7,8- tetrahydropyrido(3,4-d)pyrimidin-4-yl)-1-(2-fluoroprop2-enoyl)piperazin-2-yl)acetonitrile, 2-piperazineacetonitrile, 4-(7-(8-chloro-1-naphthalenyl)-5,6,7,8-tetrahydro-2-(((2s)-1-methyl-2-pyrrolidinyl)methoxy)pyrido(3,4-d)pyrimidin-4-yl)-1-(2-fluoro-1-oxo-2-propen-1-yl)-, (2s)-4-BROMO-3-(CARBOXYMETHOXY)-5-(4-HYDROXYPHENYL)THIOPHENE-2-CARBOXYLIC ACID
go.drugbank.com/drugs/DB07197ExperimentalSynonyms: 4-BROMO-3-(CARBOXYMETHOXY)-5-(4-HYDROXYPHENYL)THIOPHENE-2-CARBOXYLIC ACID{4-[(2R)-pyrrolidin-2-ylmethoxy]phenyl}(4-thiophen-3-ylphenyl)methanone
go.drugbank.com/drugs/DB07237ExperimentalSynonyms: {4-[(2R)-pyrrolidin-2-ylmethoxy]phenyl}(4-thiophen-3-ylphenyl)methanoneDiloxanide furoate
go.drugbank.com/drugs/DB14638ApprovedInvestigationalSynonyms: 2,2-dichloroacetamido-4-n-methylphenyl 2-furoate, 4-(n-methyl-2,2-dichloroacetamido)phenyl 2-furoateCategories: Heterocyclic Compounds, 1-RingBitolterol
go.drugbank.com/drugs/DB00901ApprovedWithdrawnIt is a beta-2-adrenergic receptor agonist. Bitolterol was withdrawn from the market by Elan Pharmaceuticals in 2001.
Categories: Adrenergic beta-2 Receptor Agonists, Selective Beta 2-adrenergic AgonistsSynonyms: 4-(2-(tert-butylamino)-1-hydroxyethyl)-o-phenylene di-p-toluate, 4-[2-(tert-butylamino)-1-hydroxyethyl]-o-phenylene di-p-toluateTideglusib
go.drugbank.com/drugs/DB12129ApprovedInvestigationalWithdrawnIt is reported to be a potent anti-inflammatory and neuroprotective that is a non-ATP competitive inhibitor of glycogen synthase kinase 3 (GSK-3).
Categories: Glycogen Synthase Kinase 3, antagonists & inhibitors, Heterocyclic Compounds, 1-RingSynonyms: 4-BENZYL-2-(A-NAPHTYL)-1,2,4-THIADIAZOLIDINE-3,5-DIONE, 4-Benzyl-2-(naphthalen-1-yl)-1,2,4-thiadiazolidine-3,5-dione(R)-3-BROMO-2-HYDROXY-2-METHYL-N-[4-NITRO-3-(TRIFLUOROMETHYL)PHENYL]PROPANAMIDE
go.drugbank.com/drugs/DB07454ExperimentalSynonyms: (R)-3-BROMO-2-HYDROXY-2-METHYL-N-[4-NITRO-3-(TRIFLUOROMETHYL)PHENYL]PROPANAMIDE